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Abstract: Genetic variants in the apolipoprotein E (APOE) gene are associated with lipid metabolism
and lipid-related traits in the non-Hispanic population. There have been limited studies regarding the
association between the APOE gene and hypercholesterolemia in the Hispanic population; therefore,
our aim for this study is to examine the APOE gene’s associations with cholesterol level and its
related phenotypes. The APOE gene consists of three different alleles, ε2, ε3, and ε4, with ε4 being
associated with dementia and cardiovascular diseases. A total of 1,382 subjects were collected from
the Texas Alzheimer’s Research and Care Consortium (TARCC, N = 1320) and the Initial Study
of Longevity and Dementia from the Rio Grande Valley (ISLD-RGV, N = 62). Questionnaires on
demographics, medical history, and blood/saliva samples were collected and APOE genotypes were
performed. We observed allele frequencies of the APOE ε3 (96.7%), ε4 (22.6%) and ε2 (6.8%) alleles,
respectively. Multivariable logistic regression revealed a significant association between the APOE ε4
allele and hypercholesteremia (p = 1.8 × 10−4 ) in our studied Hispanic population. We prove for
the first time, that the APOE ε4 allele increases the risk for hypercholesterol in Hispanics. Further
research is needed to confirm and supports our current findings.
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Several genes have been suggested for abnormal lipid and/or lipid related phenotypes;
among these candidate genes, the apolipoprotein E (APOE) gene is well documented [1,2].
The APOE genetic polymorphism involves the coding region of the APOE gene and results
in alterations in the gene product, which affect the metabolic rate of the lipoprotein particles [3,4]. APOE is a multifunctional protein, which plays an important role in lipoprotein
metabolism and has been shown to be associated with maintaining the homeostasis of
cholesterol levels and transporting lipids [5]. The genetic polymorphism of the APOE gene
is mainly attributable to three alleles, ε2, ε3, and ε4. According to a meta-analysis, the
allele frequencies of the APOE gene were found to differ in different ethnic populations [6];
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for example, the APOE ε4 allele is particularly enriched in the indigenous populations
of Central Africa (40%), Oceania (37%), Africa American (31%), and Australia (26%), and
Caribbean-Hispanic (22%), but less common in the Mediterranean area or South China
(<10%) [7,8]. However, there is a lack of studies on APOE ε4 allele frequency and its
association with cholesterol phenotypes in the U.S. Hispanic population. A recent study on
APOE gene, protein function and interaction with dietary factors suggests that APOE ε3
is most prevalent worldwide, despite the local accumulation of APOE ε4 in indigenous
populations, which may partly explain the different levels of beneficial and adverse effects
in different ethnic backgrounds [9].
Accumulated studies have demonstrated that the APOE ε4 allele is associated with several health conditions, including cholesterol-related phenotypes reported in non-Hispanic
populations. Another study has also demonstrated that total cholesterol level is higher in
APOE ε4 allele carriers compared to those with the APOE ε2 allele in the Afro-Caribbean
population [10]. It was also shown that the low-density lipoprotein cholesterol (LDL)cholesterol level is lower in APOE ε2 carriers compared to individuals with homozygotes
APOE ε3 and APOE ε4 alleles in the Afro-Caribbean population [10]. Another recent
Meta-Analysis based on 27 studies with 3136 dementia and 3103 healthy controls reported
that circulating cholesterol was significantly increased in APOE ε4 carriers in mixed populations [11]. The cholesterol-associated APOE ε4 allele was also reported in the Saudi—[12]
White—[13–16], Afro-Caribbean—[10], and Asian—[17,18] populations. The role of APOE
genetic variation on interindividual variation in the plasma cholesterol has been wellestablished, especially LDL-C in non-Hispanic White and African Black populations [19]. A
recent genome-wide association study (GWAS) indicated that APOE ε3 allele, as a common
allele, is also associated with high-density lipoprotein-cholesterol (HDL-C) and triglyceride
(TG) levels in the White population [20]. Furthermore, a research study suggests a low
frequency of APOE ε2 and ε4 alleles in the Hispanic population in comparison with nonHispanic populations. Hispanic or Latino refers to a person of Cuban, Mexican, Puerto
Rican, South or Central American, or other Spanish culture or origin regardless of race
and is an admixed population [21,22]. The APOE ε4 allele is not associated with the risk of
hypercholesterol in the U.S. Hispanic population.
Moreover, the complications of abnormal lipid levels (e.g., atherosclerosis, hypertension and/or diabetes, cardiovascular disease, CVD) were also observed to be associated
with the APOE ε4 allele in the Asian population [23]. The APOE ε4 allele and the genotypes
(ε3/ε4 and ε4/ε4) were associated with an increased risk of hypertension in different
population studies, for example, in Asians and Caucasians [6]. Likewise, the individuals
who carried the genotypes APOE ε3/ε4 and ε4/ε4, had high levels of LDL-C and increased
blood pressure [6]. To date, only one study in the Mexican population shows that the APOE
ε4 allele was associated with the lowest levels of HDL-C [24]. However, to date, there is
no study of the APOE gene in association with cholesterol-related phenotypes in the U.S.
Hispanic population.
Studies on the plasma lipid composition have shown differences between non-Hispanic
Whites and Hispanics; Hispanics have higher circulating TG and lower HDL cholesterol levels [25]. Also, a systemic review reported the higher levels of C-reactive protein
(CPR) in Hispanics than Caucasians due to differences in social economic situation and
racial/ethnicity [25,26].
Moreover, over 6 decades ago, a relationship between thyroid autoimmunity and
hyperlipidemia was suggested [27]. Therefore, we also tested the association between
thyroid-related phenotypes and hypercholesteremia in the U.S. Hispanic population.
The APOE ε4 allele is associated with lipid-related traits or diseases mainly reported
in non-Hispanic populations, which had never been explored in the Hispanic population.
Thus, the current study investigated the frequencies of the APOE alleles and studied their
relationship with cholesterol levels and lipid-related traits in the Hispanic population in
the current study.
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2. Materials and Methods
This study is an analysis of data collected by the Texas Alzheimer’s Research and Care
Consortium TARCC (N = 1320) in combination with our data, Initial Study of Longevity
and Dementia from the Rio Grande Valley (ISLD-RGV, N = 62), resulting in a total of
1382 subjects. The study protocols were approved by the corresponding Institutional Ethics
Committees and Institutional Review Boards. A written consent form was obtained from
each participant or by their legally authorized proxies, and these were gathered before data
collection began as in previous studies [28,29].
The first group of data were from ISLD-RGV. The Hispanic control subjects were
matched to cases based on age, gender, and ethnicity. Patients with hypercholesterolemia,
diabetes, other chronic disorders, and healthy subjects were recruited from the RGV, which
included the regions of Brownsville and McAllen, Texas. Participants were recruited from
local adult daycare centers and communities. In addition, questionnaires on lifestyle
(several questions [30] and medical history) modified based on [31] were also collected
during the interview.
The second group of data were collected from the TARCC study, which is a wellcharacterized, ethnically diverse sample with annual longitudinal follow-up, described
in detail in previous reports [32,33]. The participants underwent a standardized annual
examination, which included a medical evaluation, neuropsychological testing, and clinical
interview.
Phenotypes of demographics, medical history and diseases were assigned no more
than three values, denoted by 0, and 1. For example, to specify the presence or absence of
phenotypes (e.g., hypercholesterolemia, diabetes, and hypertension), the values 0 (Absent)
and 1 (Present) were given. All diagnoses were based on either self-report and/or standardized enzymatic procedures. Hypercholesterolemia was defined as follows: 0 = Absent, and
1 = Inactive/Active. Serum cholesterol > 220 mg/dL was defined as hypercholesterolemia.
Hypertension was defined as: 0 = Absent, 1 = Inactive/Active.
2.1. DNA Isolation and Genotyping
Genetic data were collected to study genetic determinants, such as APOE genotypes
and alleles. DNA extraction was performed using two different methods: 1320 blood
samples were collected from TARCC, and 62 saliva samples were collected from ISLD-RGV.
DNA isolation and genotyping of the TARCC’s samples were described in detail in previous
studies [33,34]. For the collection of ISLD-RGV saliva samples, those who consented to the
study were asked to provide 2 mL of saliva. The samples were collected using Oragene
DISCOVER (OGR-500) (DNA Genotek. Ottawa, ON, Canada), a self-collecting kit, from the
company DNA Genotek Collection and collected according to OGR-500 protocols [35]. The
saliva samples were stored at a temperature of 4 ◦ C until DNA extraction. DNA isolation
from saliva was performed following the standardized laboratory protocol described by
DNA Genotek using PrepIT® •L2P (DNA Genotek, Ottawa, ON, Canada).
The genotype for the APOE gene was determined by two separate methods. TaqMan
single-nucleotide polymorphism (SNPs) assays were used to analyze the SNPs, and rs7412
and rs429358 were used to identify the three main APOE alleles (ε3, ε2, and ε4) for the
ISLD-RGV sample. TARCC utilized the Affymetrix Genome-Wide Human SNP Array 6.0
to collect SNPs rs7412 and rs429358 data, as in previous studies [36]. The validity of the
recorded genotypes was verified by executing GWAS and a whole exome sequence (WES)
to compare replicated samples of the same pipeline [37]. SNPs data were identified as
either an ε2−, ε3−, ε4− (the minus sign states that the allele is absent) or ε2+, ε3+, ε4+ (the
plus sign “+” indicates that the allele presents), participants who carried one copy of the
allele, being heterozygous or two alleles, homozygous). From a total of 1382 participants,
only 1320 participants had APOE genotypes.
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2.2. Statistical Analyses
Statistical analysis was performed according to APOE ε2, ε3 and ε4 carriers (ε2+, ε3+,
and ε4+) and non-carriers (ε2−, ε3−, and ε4−). In total, several variables (e.g., BMI, age,
and education) were used to generate statistical reports from the studied population. The
Statistical Package for Social Sciences (SPSS) version 26 was used to perform statistical
analysis. A two-tailed t-test and chi-square analysis were used to examine the role of
each potential risk factor for cholesterol related phenotypes; then multivariable logistic
regression was used to adjust for all the potential risk factors (e.g., sex, age, and education).
To test whether the APOE alleles were independently associated with several phenotypes
(e.g., cholesterol-related traits) in the subjects, logistic regression models were constructed.
Differences with two-tailed probability values of p < 0.05 were considered to be statistically
significant. The odds ratio (OR) was used to determine the strength of associations between
alleles and phenotypes.
2.3. Power Analyses
As in our previous studies, including [38], a power analysis was estimated for known
genes using a case-control study design for discrete traits using Genetic Power Calculator [39] (https://zzz.bwh.harvard.edu/gpc/ (accessed on 1 November 2021)). The power
to detect the association between APOE alleles and phenotypes was estimated as 94%,
based on the total sample of 1333 subjects, including 860 affected subjects with disease
phenotypes (e.g., hypercholesterolemia), 460 matched control, and marker allele frequency
of 0.2 since these allele frequencies are the minor allele frequencies of the tested APOE
gene.
3. Results
3.1. Descriptive Statistics of Hypercholesterolemia
A total of 1320 out of 1382 participants had APOE genotype data. The status of the
1320 participants was classified as 860 (65.2%) participants with high cholesterol levels,
while 460 (34.8%) represented the control group in the present study. The demographic
characteristics of hypercholesterolemia and non-hypercholesterolemia are shown in Table 1. A total of 589 females and 271 males had hypercholesterolemia. The mean age of
hypercholesterolemia cases was 70.41 ± 9.12 years, which was found to be statistically
significantly older than that in the control subjects (67.20 ± 9.85, p = 3.98 × 10−9 , Table
1). The frequencies of hypertension, thyroid disease, and diabetes were statistically significantly higher in the patients with hypercholesterolemia as compared with the control
group (p < 0.002). There was no difference in body mass index (BMI) between hypercholesterolemia (BMI = 30.35 ± 9.12) and the control group (BMI = 30.37 ± 7.23).
Table 1. Results of chi-square2 analysis and t-test for demographic and health characteristics in hypercholesterolemia.
Controls
(N = 460)

Hypercholesterolemia Cases
(N = 860)

p Value

Age (mean ± SD)

67.20 ± 9.85

70.41 ± 9.12

3.98 × 10−9

Males (N, %) N = 399
Females (N, %) N = 921

128 (32.08%)
332 (36.05%)

271 (67.92%)
589 (63.95%)

0.165

BMI a (mean ± SD)

30.37 ± 7.23

30.35 ± 6.24

0.956

Hypertension (N, %) N = 874
Non-Hypertension (N, %) N = 446

231 (26.43%)
229 (51.3%)

643 (73.57%)
217 (48.7%)

<0.00001

Thyroid (N, %) N = 273
Non-Thyroid (N, %) N = 1047

73 (26.74%)
387 (37%)

200 (73.26%)
660 (63.0%)

0.002

Diabetes (N, %) N = 489
Non-Diabetes (N, %) N = 831
Education (mean ± SD)

93 (19.02%)
367 (44.2%)
9.74 ± 4.66

396 (80.98%)
464 (55.8)
10.45 ± 4.62

p value, t-test for continuous variables and chi-square test for categorical variables.
expressed as the mean ± SD.

a

<0.00001
0.518

BMI—body mass index. Numerical values are

Genes 2021, 12, 1768

5 of 9

3.2. Distributions of APOE Alleles
The study included 1382 Hispanic participants collected from the combined TARCC
and ISLD-RGV data. A total of 961 (69.8%) subjects were females and 421 (30.2%) subjects
were males. The allele frequencies of the APOE ε3 (96.7%), ε4 (22.6%) and ε2 (6.8%) alleles
were observed (Table 2), which are similar to the frequencies in the Hispanic population in
previous reports [36,37]. APOE ε4 allele status on demographics and cholesterol-related
phenotypes is displayed in Table 3. In terms of the APOE ε4 allele, a total of 20.6%
females, and 22.1% males carried at least one APOE ε4 allele (Table 3). A total of 211
(25.9%) participants with hypercholesterolemia carried at least one copy of the APOE
ε4 allele. Chi-square test revealed a significant association between APOE ε4 allele and
hypercholesterolemia (p = 1.17 × 10−4 ).
Table 2. The distributions of APOE alleles in the studied Hispanic population.
APOE ε3+

APOE ε4+

APOE ε2+

96.7%

22.6%

6.8%

APOE ε3+, ε4+, or ε2+: carrying at least one copy of APOE alleles.

Table 3. APOE ε4 allele status on demographics and cholesterol related phenotypes in our studied population.
APOE ε4 − a (N = 1042)

APOE ε4 + b (N = 278)

p Value

Age (mean ± SD)

69.33 ± 9.40

70.75 ± 9.45

0.027

Females (N, %) N = 921
Males (N, %) N = 399

731 (79.37%)
311 (77.94%)

190 (20.63%)
88 (22.06%)

0.624

Education (mean ± SD)
c BMI (mean ± SD)
Hypercholesterolemia (N, %)
Hypertension (N, %) N = 832
Diabetes (N, %) N = 459
Obese (N, %) N = 112

10.17 ± 4.62
30.44 ± 6.62
605 (74.14%)
640 (76.92%)
365 (79.52%)
88 (78.57%)

10.41 ± 4.74
29.61 ± 6.35
211 (25.86%)
192 (23.08%)
94 (20.48%)
24 (21.43%)

0.236
0.064
1.17 × 10−4
0.564
0.170
0.639

p value, t test for continuous variables and Chi-square test for categorical variables. a The APOE ε4 allele is absent (APOE ε4-).
at least one copy of APOE ε4 (APOE ε4+). c BMI- body mass index. Numerical values are expressed as the mean ± SD.

b

Carrying

3.3. Multivariable Logistic Analysis
A multivariable logistic regression analysis was performed, and the results further
supported the association between the APOE-ε4 allele and hypercholesteremia (Table 4).
After controlling for potential confounding factors (e.g., gender, education and APOE ε
allele), we observed a statistically significant association between the APOE ε4 allele and
hypercholesteremia (p = 1.8 × 10−4 ). The odds of having hypercholesteremia were 1.9-fold
higher (95% CI, 1.36–2.67), in persons with an APOE-ε4 allele compared with those without.
The APOE ε3 allele was not associated with hypercholesteremia (p = 0.484).
Table 4. Logistic Regression Analysis of Cholesterol-Related Phenotypes.
Hypercholesterolemia Group (N = 860) vs. Control Group
(N = 460)

Sex
BMI c
APOE ε3+
APOE ε4+
Education

OR a (95%CI b )

p Value

0.86 (0.65, 1.13)
1.00 (0.99, 1.02)
1.34 (0.59, 3.06)
1.90 (1.36, 2.67)
0.94 (0.75, 1.19)

0.28
0.53
0.484
1.8 × 10− 4
0.61

a OR—odds ratio, b CI—confidence interval. c BMI— body mass index. Carrying at least one copy of APOE ε4
(APOE ε4+). Carrying at least one copy of APOE ε3 (APOE ε3+).
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4. Discussion
This study demonstrates the APOE ε4 allele’s association with cholesterol in the
Hispanic population, after controlling for covariates, such as gender, BMI, APOE ε3 allele,
and education. This finding adds additional evidence to the association between the APOE
ε4 allele with hypercholesterolemia. Increasing studies suggest an association between
APOE ε4 allele and hypercholesterolemia in non-Hispanic populations. In this study, the
Hispanic participants are 96.7% APOE ε3 allele carriers, followed by APOE ε4 allele (22.6%)
and, lastly, the APOE ε2 allele (6.8%), which are comparable to the results of previous
studies in Hispanics [40,41]. In our study, the hypercholesterolemia associated APOE ε4
allele suggests that individuals carrying the APOE ε4 allele(s) are at an increased risk of
hypercholesterolemia development in the Hispanic population. Previous studies have
also marked the APOE ε4 allele as a determinant for hypercholesterolemia in the Algerian
population [42] and other non-Hispanic populations. A case-control study showed that
participants residing in Valencia, Spain, that were APOE ε4 allele carriers had a higher risk
of hypercholesterolemia than those that were not APOE ε4 allele carriers [43]. However,
there were no associations between the APOE ε4 allele and obesity and hypertension in the
our current study, which is consistent with the findings in previous reports in Mexican and
European populations [24,44,45].
This is the first report of significant findings of the APOE ε4 allele’s association with
hypercholesterolemia in the Hispanic population. A previous study of 425 Hispanic participants (193 with and 232 without cerebral amyloid angiopathy) reported a higher prevalence
of stroke and hypercholesterolemia in non-APOE ε4 allele carriers [45]. However, there
have not been more studies up to date involving Hypercholesterolemia, the APOE ε4 allele,
and the Hispanic population. A study with a much bigger sample size of 1997 Mexican
Amerindians (MA) showed an association between those MA who carried the APOE ε4
allele and a low level of HDL-C and higher levels of LDL-C [24], which partially supports
our current findings. However, we focused on total cholesterol level and patients with
hypercholesterolemia. Another study from the Kashmiri population shows that patients
with CAD carrying the ε4 allele had significantly higher total cholesterol (TC) and LDL
levels [46].
Regarding the statistical analysis of APOE ε3 allele, our study demonstrated no
significant associations between the APOE ε3 allele and obesity, hypercholesterolemia, or
CVD in our Hispanic population. Furthermore, it has been suggested that the APOE ε2
allele is considered a protective allele against CVD by lowering the levels of LDL [47,48].
In addition, cholesterol levels have been shown to regulate inflammatory and immune
processes, as shown in Chinese population [49] but little is known about their association
with thyroid disease in the Hispanic population. Based on the current study, we observed
that 73.3% of patients with hyperlipidemia are also comorbid with thyroid disease (Table 1).
Strength and Limitations
The strengths of the current study are as follows: (1) additional evidence of 22% of
APOE ε4 allele was observed, and (2) this is the first study showing that the APOE ε4 allele
increases the risk of hypercholesterol in the U.S. Hispanic population. The current results
can be used for future confirmation in a meta-analysis of this unique population. The limitations of our study consist of (1) the sample size, comprising of a total of 1382 participants,
was moderate or small in our study, although we showed a high statistical power of 94%,
after further dividing the subjects, for an example based on subjects with and without
the APOE ε4 allele. This small sample size may decrease the statistical power and lead to
a type II error [18,44], so a larger sample size is required to obtain more reliable results.
The current study is ongoing, we will continue to recruit subjects to increase statistical
power and conduct a more specific analysis, such as associations between APOE ε4 allele
or its genotypes (ε4/ε4, ε3 ε4 or ε3/ε2, etc) and several cholesterol related phenotypes
(e.g., hypertension, thyroid disease). (2) Our studied population, the Hispanics, is very
diverse and is poorly understood. Studies have observed that this ethnicity is diverse
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in genetic ancestry, culture, and environmental exposures [50]. More studies should be
made, with a larger sample size, to further prove the associations found in this study. (3)
Phenotypic heterogeneity was observed in our studied samples; for example, patients with
hypercholesterolemia may have comorbidities such as diabetes or hypertension. (4) Total
cholesterol was tested, which may have more phenotypic heterogeneity in the current study.
Therefore, studies on more specific type(s) of cholesterol such as HDL-cholesterol and
LDL-cholesterol, in association with APOE alleles, are needed in the future. (5) Cholesterol
metabolism among different APOE genotypes (e.g., ε4/ ε4, ε3/ε 4) and sex differences
in the effects of APOE alleles along the APOE pathway were not tested because reducing
the sample size would result in a loss in statistical power. This could be a future study
direction.
5. Conclusions
The current study emphasizes the prevalence of high cholesterol levels and the effects
that this may have on genetics (e.g., APOE gene) and demographics (e.g., sex, age, and
education) in the Hispanic population. The results of the current study demonstrate that
the APOE e4 allele carries a high risk for cholesterol-related traits, including hypercholesterolemia, in the Hispanic population. No associations were found between the APOE
ε3 or APOE ε2 allele and cholesterol-related traits in the current population. While this
study aims to aid doctors in the provision future care plans to detect and prevent metabolic
syndrome symptoms before it is too late, further studies are needed to confirm our current findings in this population. This work functions to highlight how the understudied
Hispanic population can further our understanding of the genetics of cholesterol-related
phenotypes.
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